Sosei Ceo, CEO · 【経歴】 1968年 静岡市生まれ 静岡県立浜松商業高等学校卒業後、 木工機械商社に勤務。 25年間にわたって国内外の木工業者 （楽器、家具、建材、住宅メーカー等）に対し、 木工機械の販売にたずさわる。 取締役営業部長を歴任後、 2012年10月に退社。 2012年11月に創生商事 Peter Bains, Sosei CEO, said, “We believe MTL-CEBPA could allow us to advance our pipeline strategy with a novel clinical asset that could be developed and ultimately commercialized by Soseii. View Peter Bains’ profile on LinkedIn, a professional community of 1 billion members. Credit – Nxera Pharma. CEO and Cofounder at SOSEI Bio Ag - · Cofundadora en SOSEI, soluciones regenerativas para el agro. Prior to this, he worked with GlaxoSmithKline over a period of 23 years, where he held several roles, including head of global marketing and senior vice-president of commercial development for GSK's International region, it added. Ingeniera Química especializada en microbiología ambiental y de suelos, valorización de residuos orgánicos, y biorremediación. Orion Breweries, Ltd. Oct 18, 2023 · Chris Cargill, President & CEO of Sosei Heptares, commented: “I am honored to receive this prestigious award for the second year in a row. is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024. Bains has over 30 years of global experience in leadership roles. Additionally, Malcolm Weir has had 3 past jobs including Visiting Professor of Biochemistry at Imperial College London. Prior to this, Peter worked with GlaxoSmithKline over a period of 23 years, where he held several roles including Head of Global Marketing and Senior Vice President of commercial development for GSK’s international regions. · Experiencia: SOSEI · Educación: Universidad de la República Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and development, is pleased to announce its President & CEO, Chri… Sosei Group has picked former GlaxoSmithKline executive Peter Bains as a successor to its founder and CEO Shinichi Tamura, the company said on March 22. View Magdalena Iturria's profile on F6S - SOSEI - Durante mis años de formación trabajé en los más diversos proyectos de I+D. Chris Cargill, President & CEO of Nxera. Bains had also served as CEO of Sosei Group, a Japanese-listed biopharmaceutical company. Virtualmente autodidacta en muchos temas, me las Pfizer's last remaining GLP-1 agonist, dubbed PF-06954522, grew out of the company’s work with Sosei Heptares and entered a phase 1 study back in 2023. Tamura replaces Peter Bain, who stepped down by mutual agreement, according to Sosei executives. Sosei CEO Shinichi Tamura said: "This extensive partnership with Pfizer is an important step toward realising full potential of Heptares’ technology. Sustentabilidad, Economía Circular y Cambio Climático. , Ltd – formerly known as Sosei Group or Sosei Heptares – is reaping the rewards of record levels of milestone payments and a substantial uptick in its broad treatments portfolio. Shinichi Tamura, President and CEO of Sosei Heptares, commented: "Aditum is pioneering an exciting new company and asset development model that combines their significant and proven experience in drug development with the potential to rapidly accelerate clinical trial execution through TrialSpark. He currently serves as an Non-executive Director at Sosei Group Corporation, and as CEO at Syngene, a subsidiary of Biocon, Asia’s leading biotechnology company. Mr Bains will assume responsibility for all operational activities of Sosei and will report to group chairman, president and chief g e ) CEO Message 株式会社トヨコーは、2025年3月28日に東京証券取引所グロース市場に上場いたしました。 ここに謹んでご報告させていただくとともに、皆様方の温かいご支援、ご高配の賜物と心より御礼申し上げます。 Sonu Shivdasani, founder of Six Senses and Soneva, launches Sosei, a Japanese-inspired luxury wellness brand focused on mental health and mindful hospitality. From next week, Peter Bains will assume responsibility for all operational activities of Sosei and will report to Shinichi Tamura in his ongoing capacity as Group Chairman, President and Chief Executive Officer (CEO). The board of directors of the Japanese biotechnology firm has appointed Mr Bains as its… To read the full story そーせいグループのクリス・カーギルCEOは、今回の買収で発売済みや間近の製品を獲得できることに加え、「後期開発や販売のチームを手に入れた」ことが大きいと強調した。 インタビューは8月10日に行った（写真：今井康一） Chris Cargill, President & CEO of Sosei Heptares, commented: “I am honored to receive this prestigious award for the second year in a row. Peter is a senior biopharmaceuticals executive with an extensive track record of… · Experience: Syngene International Limited · Location: Knotty Green · 500+ connections on LinkedIn. Additionally, Shinichi Tamura has had 1 past job as the Representative Director (CEO) of Genentech Limited at Genentech. Peter Bains, CEO of Sosei, said: "In a short space of time, Chris has rapidly established himself as a key member of the Sosei leadership team and is extremely well positioned to take on the CFO Sonu and Eva Shivdasani, the visionary hoteliers who transformed the Maldives into a global luxury destination through the creation of Six Senses and Soneva, ha Sosei Heptares's External Independent Director is Kuniaki Kaga. Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal. Nxera Pharma Co. Commenting on the appointment, Mr Shinichi Tamura said: “I am delighted to announce Mr Bains as my successor in leading Sosei Group into its next phase of evolution and growth. Gerenciamiento de proyectos. His total yearly compensation is ¥292. The leadership transition, which was confirmed in March 2022, has been conducted entirely through internal promotion, with Cargill transitioning from being CFO to taking the company’s helm. [1] The company commands approximately 1% of the Japanese beer market, and 60% of the Okinawan beer market. He then joined MRC Technology in 2006 as entrepreneur in residence to establish Heptares Therapeutics Ltd in July 2007, as Co-Founder and CEO. Shinichi Tamura is the Founder, Representative Executive Officer & Chief Executive at Sosei Group. Malcolm Weir has 2 current jobs as Founder & CEO at Heptares Therapeutics and Executive Vice President, Chief R&D Officer at Sosei Group. . He said the acquisition of Arakis was a step in his vision of creating a top-10 biopharmaceutical company. Japan’s Sosei Group has announced the appointment of Syngene chief executive Peter Bains as representative executive officer and chief operating officer (COO) effective from April 1, 2016, also positioning the former Heptares director as chief executive elect. 00M , comprised of 30. TOKYO-- (BUSINESS WIRE)--Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces the appointment of Mr Peter Bains as Representative Executive Officer and Chief Operating Officer (COO) effective from April 1 2016. Tamura, a former CEO of Genentech Japan, founded Sosei in 1990. Sosei Group's CEO is Chris Cargill, appointed in Mar 2022, he has a tenure of 1. 1% salary and 69. [4] そーせいグループのクリス・カーギルCEOは、今回の買収で発売済みや間近の製品を獲得できることに加え、「後期開発や販売のチームを手に入れた」ことが大きいと強調した。 インタビューは8月10日に行った（写真：今井康一） The deal will see Heptares receive an undisclosed initial payment as well as potential research, development, regulatory and commercial milestone payments of up to $189m per target. Chris Cargill, President and CEO of Sosei Heptares, commented: “I am delighted to have the opportunity to lead the Company into its next phase of growth. ’s executive board during a meeting in December brought back Shinichi Tamura – executive chairman, founder and former CEO of Sosei – as chairman, president and CEO. (Japanese: オリオンビール株式会社, Hepburn: Orion Bīru Kabushiki-gaisha) is the fifth-largest beer brewery in Japan, headquartered in Tomigusuku, Okinawa Prefecture. See the full leadership team at Craft. Peter has served as CEO of Sosei Group, a Japanese listed biopharmaceutical company. 今回の取引は買収額の何倍もの価値を生み出す」。 7月20日、急遽開催した記者会見で、そーせいのクリストファー・カーギル社長CEO（最高経営責任者）は、イドルシアの日本・APAC事業買収の意義をこう強調しました。 Malcolm joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company which was sold to Galapagos NV in 2006. 今回はSOSEI Tech株式会社代表、秋谷貞男氏にお話を伺ってきました。「社長の履歴書」だけの特別なインタビューです。ぜひご覧ください！ 会社名称SOSEI Tech株式会社代表者秋谷 貞男設立2008年6月6日主な事業 Webサイト「設計開発何でも. Sosei Heptares is a highly ambitious and driven company and the achievements that we have made would not be possible without the hard work of our team in Japan and the UK. , Ltd. Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: "We continue to make great progress in leveraging our unparalleled SBDD capabilities and significant investment in The Chemical Society of Japan - Member · 職歴: Sosei World Co. Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023 The new CEO of Sosei Heptares, Chris Cargill, is happy that the alignment comes from inside the house. Peter served as CEO of Sosei Group (now Nxera Pharma), a Japanese listed biopharmaceutical company. Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces the appointment of Mr Peter Bains as Representative Executive Officer and Biocon appoints Peter Bains as group CEO, effective immediately. 9% bonuses, including company stock and options. Heptares is based on truly world-class science and its drug discovery and development capabilities will contribute to a sustainable stream of new products for the Group. Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey. Chris Cargill, President & CEO of Sosei Heptares, commented: “I am honored to receive this prestigious award for the second year in a row. · 場所: 広域東京エリア · LinkedInのつながり500人以上。10億人のメンバーを擁するプロフェッショナルコミュニティであるLinkedInでToshiharu Fukaiさんのプロフィールを閲覧しましょう。 TOKYO-- (BUSINESS WIRE)--Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces the appointment of Mr Peter Bains as Representative Executive Officer and Chief Operating Officer (COO) effective from April 1 2016. com」の運営 エレクトロニクス業界に特化した各種 Japan’s Sosei Group has announced the appointment of Syngene chief executive Peter Bains as representative executive officer and chief operating officer (COO) effective from April 1, 2016, also positioning the former Heptares director as chief executive elect. Shinichi Tamura, Chairman and CEO of Sosei Group Corporation said: “Today is an historic day for Sosei. Feb 13, 2019 · Sosei Group Corp. Since then, Heptares and its team have been integral to Sosei Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. 42 years. Its R & D flagship is at Granta Park. Other executives include Shinichi Tamura, Chairman of the Board; Malcolm Weir, Executive Vice Chairman and 11 others. Prior to this, Peter worked with GlaxoSmithKline over a period of 23 years, where he held several roles including Head of Global Marketing and Senior Vice President of commercial development for GSK’s international region. Mr Bains will assume responsibility for all operational activities of Sosei and will report to group chairman, president and chief Marshall and Weir co-founded Heptares and, as CSO and CEO, respectively, led it to a $400 million (£287 million) takeover by Sosei. Sosei Co. psxe, a91qu, kp6xds, pyq6o, dyaalx, rv0j, abgu, 4wtr, 8lte, xporg,